CYP7A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16600055	0.66	2/20
SCHEMBL16600056	0.66	2/20
SCHEMBL16608395	0.66	2/20
SCHEMBL16599796	1.00	1/20
SCHEMBL16599798	1.00	1/20
SCHEMBL16608239	1.00	1/20
SCHEMBL17923053	1.00	1/20
SCHEMBL17959089	1.00	1/20
SCHEMBL16600060	0.86	1/20
SCHEMBL16600061	0.86	1/20
SCHEMBL16608565	0.86	1/20
SCHEMBL16599863	0.83	1/20
SCHEMBL16599865	0.83	1/20
SCHEMBL16608221	0.83	1/20
SCHEMBL16599720	0.80	1/20
SCHEMBL16599723	0.80	1/20
SCHEMBL16600116	0.80	1/20
SCHEMBL16600117	0.80	1/20
SCHEMBL16608216	0.80	1/20
SCHEMBL16608555	0.80	1/20

Clinical trials — most relevant to CYP7A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate	PHASE4	NOT_YET_RECRUITING
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing	PHASE4	COMPLETED
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis	PHASE2	ACTIVE_NOT_RECRUITING
3 Month PHI PAD PoM Study	PHASE2	COMPLETED
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors	PHASE1/PHASE2	UNKNOWN
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
Drug Interaction and Food Effect Study of CS0159	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors	PHASE1	RECRUITING
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus	nan	COMPLETED
Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot	nan	UNKNOWN
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum	nan	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response	nan	ENROLLING_BY_INVITATION
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant	nan	RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Cholesterol Metabolites as Markers for CYP3A Induction	nan	COMPLETED
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP7A1 binder may also engage these)

Protein	Name	Similarity
P46634	—	1.000	P46634 →
Q64505	—	0.999	Q64505 →
P51542	—	0.996	P51542 →
O46491	—	0.994	O46491 →
P18125	—	0.993	P18125 →
Q9JKJ9	—	0.983	Q9JKJ9 →
Q9NYL5	—	0.981	Q9NYL5 →
CYP7B1	Cytochrome P450 7B1	0.981	landscape →
P00189	—	0.978	P00189 →
F1RE08	—	0.977	F1RE08 →
P14137	—	0.974	P14137 →
O64698	—	0.974	O64698 →
PTGIS	Prostacyclin synthase	0.973	landscape →
O88962	—	0.972	O88962 →
CYP8B1	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase	0.971	landscape →
Q9EPT4	—	0.971	Q9EPT4 →
Q2XV99	—	0.971	Q2XV99 →
Q9QZ82	—	0.971	Q9QZ82 →
O02766	—	0.971	O02766 →
P10612	—	0.970	P10612 →
Q60991	—	0.969	Q60991 →
Q7YRB2	—	0.969	Q7YRB2 →
Q9PUB4	—	0.969	Q9PUB4 →
O55127	—	0.969	O55127 →
Q29626	—	0.969	Q29626 →
Q1T7C2	—	0.969	Q1T7C2 →
P79202	—	0.969	P79202 →
P79739	—	0.969	P79739 →
CYP51A1	Lanosterol 14-alpha demethylase	0.969	landscape →
CYP11A1	Cholesterol side-chain cleavage enzyme, mitochondrial	0.968	landscape →